Glenmark Pharmaceuticals received the “Indian Pharma Innovation of the Year” Award from the Government of India, as the part of the Indian Pharma & India Medical Device Awards 2021, it announced in a press release.
The 6th edition of the annual awards is jointly organized by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, The Federation of Indian Chambers of Commerce & Industry (FICCI) and Invest India.
The award acknowledges Glenmark’s patents and innovations over the last three years, in its core therapy areas of Dermatology, Respiratory and Oncology. It also recognizes the company’s contribution to the healthcare sector, in meeting both pressing and long-term patients needs.
Commenting on the award win, Mr. Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said, “Now more than ever, we see the need for continuous innovation in pharma and healthcare to address infectious and chronic diseases. Our goal at all times is to be future-ready, and to this end, innovation is ingrained in all our efforts. We thank the government for its recognition; it serves as an encouraging reminder to keep up our good work in India and the world.”
Glenmark earlier won awards from the Department of Pharmaceuticals under the categories of Indian Pharma Leader Award (2015), Company of the Year (2016), and Corporate Social Responsibility Program of the Year (2017).
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. For more information, visit www.glenmarkpharma.com .